No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases

(ECOG-ACRIN Cancer Research Group) The results of the ECOG-ACRIN Cancer Research Group's phase three trial, E2810, show no disease-free survival benefit with the use of one year of pazopanib in patients with metastatic renal cell carcinoma (kidney cancer) who had no evidence of disease following surgery to remove further metastases. There was a trend toward decreased overall survival with pazopanib.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news